semaglutide and meloxicam Can be used safely in scleroderma patients with a history of stroke or cerebrovascular risk factors? followed 24 hours later by meloxicam oral suspension at 0.045 mg/lb (0.1 mg/kg) body weight once daily New Medication Release of Symbravo

British journal of pharmacology , 134 (8), 17051710

McIntyre R

African ancestry GWAS identifies new loci not previously identified with European GWAS data During our investigation into the genetic factors contributing to POAG within the African ancestry group (1,339 POAG cases, 69,491 controls), we uncovered novel associations that highlight the intricate genetic complexity and remarkable diversity present in POAG genes in different populations

What GLP-1 Medications Cannot Guarantee A specific amount of weight loss for every individual Results identical to clinical trial averages Long-term weight maintenance without continued effort and follow-up Clinical trials typically combined medication with reduced-calorie diets, increased physical activity, and nutritional counseling

Reviewed by Tamar Rodney, PhD, PMHNP-BC, CNE, Mental Health Nurse Practitioner